OCU410 - (ArMaDa)

Aug. 25, 2026: Ocugen, Inc. (NASDAQ: OCGN) announced upcoming September 2026 conference presentations. At the Retina Society 59th Annual Scientific Meeting in Los Angeles on Sept. 24, 2026, Dr. Raj K. Maturi is scheduled to present “Safety and Efficacy of Subretinal OCU410 Gene Therapy for Geographic Atrophy: 12-Month Randomized Phase 2 ArMaDa Results,” indicating a planned clinical data presentation for OCU410 in geographic atrophy.

The company also said CEO Dr. Shankar Musunuri will participate in two investor conferences focused on its modifier gene therapy platform: the Citi 2026 Biopharma Back to School Conference in New York on Sept. 9, 2026 (fireside chat, 3:40–4:15 p.m. ET) and the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 15, 2026 (fireside chat, 3:00–3:30 p.m. ET).

Webcasts for the Citi and H.C. Wainwright events will be available on the company’s investor website, with replays accessible for 30 days.